Skip to main content

Glycosylation of proteinase 3 (PR3) is not required for its reactivity with antineutrophil cytoplasmic antibodies (ANCA) in Wegener's granulomatosis

Publication ,  Journal Article
Finkielman, JD; Merkel, PA; Schroeder, D; Hoffman, GS; Spiera, R; St. Clair, EW; Davis, JC; McCune, WJ; Lears, A; Ytterberg, SR; Hummel, AM ...
Published in: Clinical and Experimental Rheumatology
November 30, 2009

Objective. The glycosylation status of autoantigens appears to be crucial for the pathogenesis of some autoimmune diseases, since carbohydrates play a crucial role in the distinction of self from non-self. Proteinase 3 (PR3), the main target antigen for anti-neutrophil cytoplasmic antibodies (ANCA) in patients with Wegener's granulomatosis (WG), contains two Asn-linked glycosylation sites. The present study explores the influence of the glycosylation status of PR3 on the PR3 recognition by ANCA in a well characterized population of patients with WG. Methods. Forty-four patients with WG (459 serum samples) who participated in a multicenter randomized trial, were tested by capture ELISA for ANCA against PR3 and de glycosylated recombinant variants of PR3. Results. The patients were followed for a median of 27 months, and the median number of serum samples per patient was 10. At baseline, the correlation between the levels of ANCA against PR3 and against all the deglycosylated recombinant variants of PR3 were greater than 0.94 (p<0.001 for all the comparisons). Longitudinal analyses comparing the levels of ANCA against PR3 versus all the deglycosylated recombinant variants of PR3, using linear mixed models, showed no significant statistical differences (ρ≥0.90 in all cases). Conclusions. The glycosylation status of PR3 has no impact on its recognition by ANCA in WG. © Copyright Clinical and Experimental Rheumatology 2009.

Duke Scholars

Published In

Clinical and Experimental Rheumatology

ISSN

0392-856X

Publication Date

November 30, 2009

Volume

27

Issue

1 SUPPL. 52

Related Subject Headings

  • Arthritis & Rheumatology
  • 3202 Clinical sciences
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Finkielman, J. D., Merkel, P. A., Schroeder, D., Hoffman, G. S., Spiera, R., St. Clair, E. W., … Specks, U. (2009). Glycosylation of proteinase 3 (PR3) is not required for its reactivity with antineutrophil cytoplasmic antibodies (ANCA) in Wegener's granulomatosis. Clinical and Experimental Rheumatology, 27(1 SUPPL. 52).
Finkielman, J. D., P. A. Merkel, D. Schroeder, G. S. Hoffman, R. Spiera, E. W. St. Clair, J. C. Davis, et al. “Glycosylation of proteinase 3 (PR3) is not required for its reactivity with antineutrophil cytoplasmic antibodies (ANCA) in Wegener's granulomatosis.” Clinical and Experimental Rheumatology 27, no. 1 SUPPL. 52 (November 30, 2009).
Finkielman JD, Merkel PA, Schroeder D, Hoffman GS, Spiera R, St. Clair EW, et al. Glycosylation of proteinase 3 (PR3) is not required for its reactivity with antineutrophil cytoplasmic antibodies (ANCA) in Wegener's granulomatosis. Clinical and Experimental Rheumatology. 2009 Nov 30;27(1 SUPPL. 52).
Finkielman, J. D., et al. “Glycosylation of proteinase 3 (PR3) is not required for its reactivity with antineutrophil cytoplasmic antibodies (ANCA) in Wegener's granulomatosis.” Clinical and Experimental Rheumatology, vol. 27, no. 1 SUPPL. 52, Nov. 2009.
Finkielman JD, Merkel PA, Schroeder D, Hoffman GS, Spiera R, St. Clair EW, Davis JC, McCune WJ, Lears A, Ytterberg SR, Hummel AM, Viss MA, Peikert T, Stone JH, Specks U. Glycosylation of proteinase 3 (PR3) is not required for its reactivity with antineutrophil cytoplasmic antibodies (ANCA) in Wegener's granulomatosis. Clinical and Experimental Rheumatology. 2009 Nov 30;27(1 SUPPL. 52).

Published In

Clinical and Experimental Rheumatology

ISSN

0392-856X

Publication Date

November 30, 2009

Volume

27

Issue

1 SUPPL. 52

Related Subject Headings

  • Arthritis & Rheumatology
  • 3202 Clinical sciences
  • 1103 Clinical Sciences